## Abstract Despite earlier detection and recent advances in surgery and radiation, prostate cancer is second only to lung cancer in male cancer deaths in the United States. Hormone therapy in the form of medical or surgical castration remains the mainstay of systemic treatment in prostate cancer.
Prostate cancer cells use genetic and epigenetic mechanisms for progression to androgen independence
✍ Scribed by Horacio Murillo; Lucy J. Schmidt; Melissa Karter; Kari A. Hafner; Yasushi Kondo; Karla V. Ballman; George Vasmatzis; Robert B. Jenkins; Donald J. Tindall
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- English
- Weight
- 799 KB
- Volume
- 45
- Category
- Article
- ISSN
- 1045-2257
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Studies on the genetic basis of prostate cancer (PCa) have lead to mixed results with the only consensus being that PCa is a complex disease. Our goal was to gain insight into potential events involved in the acquisition of the androgen‐refractory phenotype in PCa cells regardless of DNA‐change dependence. To this end, we examined two LNCaP PCa cell line models of progression—one developed in vivo and one developed in vitro—using molecular cytogenetic and microarray gene expression analyses and extended this investigation of specific events into PCa tumors. The chromosomal changes observed in both in vivo and in vitro androgen‐independent cell lines are similar to those seen in PCa during tumor progression. Correspondingly, gene expression analysis showed significant heterogeneity in the genes expressed among androgen‐independent cells, but with some common gene expression changes that correlated with the acquired androgen‐independent phenotype. Thus, growth conditions under which the cells progress appeared to impact the mechanisms used for progression, albeit within tumor‐type‐specific pathways. Our findings suggest that a dynamic and adaptable combination of epigenetic and DNA‐change‐dependent events can be used by PCa cells for the acquisition of the androgen‐independent phenotype. This article contains Supplementary Material available at http://www.interscience.wiley.com/jpages/1045‐2257/suppmat. © 2006 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
## BACKGROUND. Differences in gene expression in prostate cells are believed to be secondary to epithelial-stromal interactions. We theorized that bone matrix may provide a fertile "soil" for prostate cancer by inducing androgen-dependent genes and allowing for androgen-independent growth. METHODS
## Abstract Androgen and androgen receptor (AR) are involved in growth of normal prostate and development of prostatic diseases including prostate cancer. Androgen deprivation therapy is used for treating advanced prostate cancer. This therapeutic approach focuses on suppressing the accumulation of
## Abstract Androgen‐ablation is a most commonly prescribed treatment for metastatic prostate cancer but it is not curative. Development of new strategies for treatment of prostate cancer is limited partly by a lack of full understanding of the mechanism by which androgen regulates prostate cancer